| P2093 | author name string | Cao Yang | |
| | Edwin Choy | |
| | Zhenfeng Duan | |
| | Henry Mankin | |
| | Francis Hornicek | |
| | Jacson Shen | |
| | Shunan Ye | |
| P2860 | cites work | Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Calpha antisense oligonucleotide | Q22008744 |
| | The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases | Q24319848 |
| | IGF binding proteins in cancer: mechanistic and clinical insights | Q28237971 |
| | Lost in transcription: p21 repression, mechanisms, and consequences | Q28251319 |
| | Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication | Q28611456 |
| | The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA | Q29615251 |
| | Targeting multidrug resistance in cancer | Q29616803 |
| | Cellular processing of platinum anticancer drugs | Q29617899 |
| | Insulin and insulin-like growth factor signalling in neoplasia | Q29619495 |
| | Molecular determinants of treatment response in human germ cell tumors | Q33185999 |
| | The coordinate regulation of the p53 and mTOR pathways in cells | Q33840457 |
| | Novel mechanisms of drug resistance in leukemia | Q33864560 |
| | Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach | Q33925323 |
| | Rescue of MHC-1 antigen processing machinery by down-regulation in expression of IGF-1 in human glioblastoma cells | Q34634158 |
| | Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy | Q35042972 |
| | Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation | Q35060814 |
| | Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy | Q35214619 |
| | p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer | Q36135594 |
| | Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. | Q36277346 |
| | The modulation of inter-organelle cross-talk to control apoptosis | Q36513159 |
| | Chemotherapy resistance in osteosarcoma: current challenges and future directions. | Q36532115 |
| | Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. | Q36536479 |
| | DNA damage-induced cell death by apoptosis. | Q36561337 |
| | WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases | Q36570903 |
| | Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. | Q37397276 |
| | Overcoming drug resistance by enhancing apoptosis of tumor cells. | Q37481518 |
| | Nanoparticles: a promising modality in the treatment of sarcomas. | Q37761069 |
| | p53: the attractive tumor suppressor in the cancer research field | Q37824262 |
| | Molecular mechanisms of cisplatin resistance | Q37926477 |
| | Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy | Q37975246 |
| | Interleukin-6 signaling pathway in targeted therapy for cancer | Q38014987 |
| | Ionizing radiation-induced responses in human cells with differing TP53 status | Q38162722 |
| | p53 as a target for the treatment of cancer. | Q38279586 |
| | Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways | Q39077231 |
| | Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer | Q39383358 |
| | Direct induction of apoptosis using an optimal mitochondrially targeted p53. | Q39387682 |
| | Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function | Q39976649 |
| | Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J. | Q40209979 |
| | Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin | Q40364572 |
| | Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells | Q40399026 |
| | Characterization of salvicine-resistant lung adenocarcinoma A549/SAL cell line | Q40555425 |
| | Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. | Q40788757 |
| | Apoptosis-promoting gene (bax) transfer potentiates sensitivity of squamous cell carcinoma to cisplatin in vitro and in vivo | Q40935658 |
| | Cell cycle-dependent regulation of nuclear p53 traffic occurs in one subclass of human tumor cells and in untransformed cells | Q41170917 |
| | An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. | Q42797525 |
| | p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax. | Q44511919 |
| | Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy | Q44667120 |
| | Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression | Q46709821 |
| | A universal gene carrier platform for treatment of human prostatic carcinoma by p53 transfection | Q50464048 |
| | Gli2 and p53 cooperate to regulate IGFBP-3- mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. | Q51929126 |
| | Mechanisms of resistance to apoptosis in human AML blasts: the role of differentiation-induced perturbations of cell-cycle checkpoints. | Q52538783 |
| | Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. | Q52561781 |
| | Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance | Q58282980 |
| | Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell Lines | Q72561176 |
| | Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome | Q81166001 |
| P433 | issue | 2 | |
| P921 | main subject | multiple drug resistance | Q643839 |
| | overexpression | Q61643320 |
| P304 | page(s) | 349-356 | |
| P577 | publication date | 2015-12-23 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines | |
| P478 | volume | 77 | |